Anti-Rt CD28 PE

• Clone:

  JJ319

• Format:

  PE

• Buffer:

  Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

• References & Citations:

  *Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, Soulillou JP, Vanhove B: Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood. 2002 Mar 15;99 (6) :2228-34., URL: http://www.ncbi.nlm.nih.gov/pubmed/11877302 , *Laskowski IA, Pratschke J, Wilhelm MJ, Dong VM, Beato F, Taal M, Gasser M, Hancock WW, Sayegh MH, Tilney NL: Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol. 2002 Feb;13 (2) :519-27., URL: http://www.ncbi.nlm.nih.gov/pubmed/11805183 , *van den Brandt J, Wang D, Reichardt HM: Resistance of single-positive thymocytes to glucocorticoid-induced apoptosis is mediated by CD28 signaling. Mol Endocrinol. 2004 Mar;18 (3) :687-95., URL: http://www.ncbi.nlm.nih.gov/pubmed/14701943 , *Kerstan A, Armbruster N, Leverkus M, Hünig T: Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3. J Immunol. 2006 Dec 1;177 (11) :7689-97., URL: http://www.ncbi.nlm.nih.gov/pubmed/17114439 , *Guillonneau C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, Usal C, Veziers J, Anegon I, Vanhove B: Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol. 2007 Dec 15;179 (12) :8164-71., URL: http://www.ncbi.nlm.nih.gov/pubmed/18056359 , *Dengler TJ, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl CF, Hünig T, Meuer SC: Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation. 1999 Feb 15;67 (3) :392-8., URL: http://www.ncbi.nlm.nih.gov/pubmed/10030284 , *Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hünig T: Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med. 2003 Apr 21;197 (8) :955-66., URL: http://www.ncbi.nlm.nih.gov/pubmed/12707299 , *Tacke M, Hanke G, Hanke T, Hünig T: CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol. 1997 Jan;27 (1) :239-47., URL: https://www.ncbi.nlm.nih.gov/pubmed/9022025, *Robinson LE, Clandinin MT, Field CJ: R3230AC rat mammary tumor and dietary long-chain (n-3) fatty acids change immune cell composition and function during mitogen activation. J Nutr. 2001 Jul;131 (7) :2021-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/11435524